indocyanine green has been researched along with atovaquone in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Du, Q; Li, Q; Luan, Y; Qin, X; Ren, X; Wang, N; Zhang, M; Zhao, Z | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for indocyanine green and atovaquone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for indocyanine green and atovaquone
| Article | Year |
|---|---|
A mitochondrial-metabolism-regulatable carrier-free nanodrug to amplify the sensitivity of photothermal therapy.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Atovaquone; Breast Neoplasms; Cell Line, Tumor; Female; Indocyanine Green; Mice, Inbred BALB C; Mitochondria; Nanoparticles; Oxidative Phosphorylation; Photosensitizing Agents; Photothermal Therapy | 2021 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |